Oncology · Monoclonal AntibodyRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for DARZALEX by Janssen Biotech

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen Biotech1 signalView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/20/2026, 6:31:55 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for DARZALEX is a significant regulatory milestone that could strengthen Janssen's competitive position in the oncology sector. Portfolio teams must stay vigilant as this development may trigger shifts in market dynamics and competitive strategies. Regulatory context from FDA (FDA AP — DARZALEX (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market shifts and competitive responses as new indications for DARZALEX are explored. The strongest clinical anchor is Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Monoclonal Antibody, 7 regulatory and 4 competitive items passed relevance filtering for Janssen Biotech.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Supplement Application for YERVOY (ipilimumab) (Humanexa Signals) — sponsor/company relevance (bristol myers squibb). Secondary pressure from FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application. This acceptance may enhance Janssen's position in the oncology market, particularly in therapies for multiple myeloma.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DARZALEX (SUPPL) (FDA). Entity match (janssen biotech). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval status remains pending and will require close monitoring.

Key Risks

Elevated medium regulatory exposure for Janssen Biotech could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, the new indications for DARZALEX could lead to increased revenue and market share in the oncology space, particularly for multiple myeloma treatments.
Oncology · Immune Checkpoint Inhibitor · Regulatory Approval · This acceptance may enhance Bristol Myers Squibb's position in the oncology market, particularly in combination therapies.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for Janssen Biotech may improve if Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any announcements regarding the approval status of the supplemental application.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DARZALEX (SUPPL)
FDAhigh relevance
Entity match (janssen biotech)
FDA document
View source
FDA AP — DARZALEX (SUPPL)
FDAhigh relevance
Entity match (janssen biotech)
FDA document
View source
FDA AP — LAZCLUZE (SUPPL)
FDAhigh relevance
Entity match (janssen biotech)
FDA document
View source
FDA AP — TECVAYLI (SUPPL)
FDAhigh relevance
Entity match (janssen biotech)
FDA document
View source
FDA AP — TREMFYA (SUPPL)
FDAhigh relevance
Entity match (janssen biotech)
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ASk Questions in GYnecologic Oncology (ASQ-GYO)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Supplement Application for YERVOY (ipilimumab)
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
NMR detects clustering and ultra-weak excipient interactions governing monoclonal antibody viscosity in formulation-relevant conditions.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen Biotech
DARZALEX

Commercial impact

medium

If approved, the new indications for DARZALEX could lead to increased revenue and market share in the oncology space, particularly for multiple myeloma treatments.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval status remains pending and will require close monitoring.

What to watch

Monitor the FDA's review timeline and any announcements regarding the approval status of the supplemental application.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.